STEADY-PD III study has been completed!

Study results will be released to the public in early May 2019!

What is the STEADY-PD III Study?
Efficacy of Isradipine in early Parkinson Disease

The Parkinson Study Group (PSG) is conducting a study of the research medication isradipine in persons who have a recent diagnosis of Parkinson disease (PD). Isradipine is a medication that is approved for the treatment of high blood pressure by the Food and Drug Administration Agency (FDA), but not for the treatment of PD. STEADY-PD III is designed to determine the  effectiveness of isradipine on slowing the  progression of PD.

Approximately 56 research centers across the United States and Canada will enroll up to 336 subjects for 36  months each.

This study is under a research grant award from the National Institute of Neurological Disorders and Stroke.

 For more information please call, 1-855-825-3390 or email us at STEADYPD3!